As mutant IDH requires NADPH to produce D-2HG, thus, a NADK inhibitor might be a novel therapeutic approach for treating mutant IDH cancer cells to decrease the NADPH pool which may not be sufficient to facilitate the production of the D-2HG oncometabolite. Here, IDH1 is linked to cancer.